Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma

Trial Profile

Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Selinexor (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2019.
    • 28 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
    • 10 Mar 2017 According to a Karyopharm Therapeutics media release, the FDA has placed selinexor (KPT-330) trials on partial clinical hold due to incomplete information in the existing version of the investigator's brochure (IB), Karyopharm has amended the IB and updated the informed consent documents accordingly and submitted to the FDA as requested.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top